WEB-APPENDIX 1

DETAILS OF THE LOGISTIC REGRESSION MODELS

Data-sharing rates over time	
Dependent variable	Intent to share (binary variable: yes/no) (**model 1**)
Explanatory variable of interest	Time (continuous variable, or qualitative if required)
Other explanatory variables	Geographical zone, intervention type, control group type, medical specialty, result on the primary outcome, funding source, sample size

Appendix Table 1: Reminder of the statistical analysis plan for the model 1

Model	**Univariate model 1**	**Multivariate model 1**
	Logistic	Mixed logistic
Constant	0.303 (0.332) p = 0.362	0.128 (0.976) p = 0.896
Date difference (years)	-0.002 (0.052) p = 0.977	-0.021 (0.073) p = 0.778
Intervention type (device)		
Intervention type (drug)		
Geographical zone (Europe)		1.319 (0.929) p = 0.156
Geographical zone (other)		1.704 (1.107) p = 0.124
Geographical zone (USA)		0.670 (0.874) p = 0.443
Control group type (inactive)		
Medical specialty (surgery)		-2.411 (1.646) p = 0.143
Primary outcome (positive)		-0.594 (0.455) p = 0.192
Funding source (charity)		
Funding source (industry)		
Funding source (mixed)		
Sample size		
Observations	185	185
Log likelihood	-126.254	-118.716
AIC	256.509	253.432

Appendix Table 2: Details of the logistic regression models (model 1)

WEB-APPENDIX 2

DETAILS OF THE SURVIVAL MODELS

3	Primary	Reuse of the data (limited to citing papers where the first, last and corresponding authors are not among the authors of the original paper)
Dependent variable		Data reused in any secondary use (re-analysis, secondary analysis, meta-analysis on IPD or pooled analysis) (censored variable / from date of publication to date of citation searches) (**model 2**). *Supplementary analysis:* Data reused in any secondary use (re-analysis, secondary analysis, meta-analysis on IPD or pooled analysis, meta-analysis on aggregate data) (censored variable / from date of publication to date of citation searches) (**model 3**).
Explanatory variable of interest		Intent to share (binary variable)
Other explanatory variables		Geographical zone, intervention type, control group type, medical specialty, result on the primary outcome, funding source, sample size

4.1	Secondary	Components (1, 2, and 3) of the primary outcome
Dependent variable		2 models will be performed: 1/ Data reused in a secondary analysis (censored variable / from date of publication to date of citation searches) (**model 4**). 2/ Data reused in a meta-analysis on individual patient data or pooled analysis (censored variable / from date of publication to date of citation searches) (**model 5**). As there was no re-analysis, this outcome won't be explored by modelling. *Supplementary analysis:* Data reused in a meta-analysis on aggregate data (censored variable / from date of publication to date of citation searches) (**model 6**).
Explanatory variable of interest		Intent to share (binary variable)
Other explanatory variables		Geographical zone, intervention type, control group type, medical specialty, result on the primary outcome, funding source, sample size

4.2	Secondary	Reuse of the data without the authorship restriction used for the primary outcome
Dependent variable		Data reused in any secondary use (re-analysis, secondary analysis, meta-analysis on IPD or pooled analysis) (censored variable / from date of publication to date of citation searches) (**model 7**). *Supplementary analysis:* Data reused in any secondary use (re-analysis, secondary analysis, meta-analysis on IPD or pooled analysis, meta-analysis on aggregate data) (censored variable / from date of publication to date of citation searches) (**model 8**).
Explanatory variable of interest		Intent to share (binary variable)
Other explanatory variables		Geographical zone, intervention type, control group type, medical specialty, result on the primary outcome, funding source, sample size

Appendix Table 3: Reminder of the statistical analysis plan for the models 2 to 8

Model	Univariate model 2	Multivariate model 2	Univariate model 3	Multivariate model 3
	Cox PH	Cox PH	Cox PH	Frailty (gaussian random effect)
Intent to share (yes)	-0.102 (0.394) p = 0.795	0.042 (0.403) p = 0.916	-0.041 (0.183) p = 0.823	-0.05337 (0.2398) p = 0.8200
Intervention type (device)		1.247 (0.808) p = 0.123		
Intervention type (drug)		0.895 (0.451) p = 0.048		
Geographical zone (Europe)				
Geographical zone (other)				
Geographical zone (USA)				
Control group type (inactive)				-0.25839 (0.2754) p = 0.3500
Medical specialty (surgery)				1.52607 (0.7533) p = 0.0430
Primary outcome (positive)		0.617 (0.477) p = 0.196		
Funding source (charity)				-0.14762 (0.5101) p = 0.7700
Funding source (industry)				-0.04208 (0.3598) p = 0.9100
Funding source (mixed)				-0.50619 (0.2717) p = 0.062
Sample size				
Observations	185	185	185	185
Log likelihood	-126.257	-123.036	-550.309	-488.800
AIC	254.515	254.072	1102.618	991.601

Appendix Table 4: Details of the survival models (models 2 and 3)

Model	Univariate model 4	Multivariate model 4	Univariate model 5	Multivariate model 5	Univariate model 6	Multivariate model 6
	Cox PH	Frailty (gamma random effect)	Cox PH	Frailty (gaussian random effect)	Cox PH	Frailty (gaussian random effect)
Intent to share (yes)	0.021 (0.540) p = 0.969	-0.03737 (0.5622) p = 0.947	-0.126 (0.518) p = 0.808	0.20741 (6.094e-01) p = 0.734	-0.063 (0.187) p = 0.738	-0.14786 (0.2531) p = 0.56000
Intervention type (device)				0.91597 (1.341e+00) p = 0.49		
Intervention type (drug)				0.99228 (7.467e-01) p = 0.18		
Geographical zone (Europe)				23.35417 (5.730e+04) p = 1.00		
Geographical zone (other)				21.60758 (5.730e+04) p = 1.00		
Geographical zone (USA)				21.91384 (5.730e+04) p = 1.00		
Control group type (inactive)						-0.20649 (0.2876) p = 0.47000
Medical specialty (surgery)						1.83425 (0.7993) p = 0.02200
Primary outcome (positive)				1.11365 (7.247e-01) p = 0.12		
Funding source (charity)				-22.75926 (6.728e+04) p = 1.00		-0.01488 (0.5408) p = 0.98000
Funding source (industry)				1.12214 (8.174e-01) p = 0.17		0.01061 (0.3874) p = 0.98000
Funding source (mixed)				0.03154 (7.013e-01) p = 0.96		-0.56351 (0.2899) p = 0.05200
Sample size						
Observations	185	185	185	185	185	185
Log likelihood	-69.458	-61.35764	-72.830	-53.76738	-528.987	-456.0038
AIC	140.915	126.715	147.660	129.535	1059.974	926.008

Appendix Table 5: Details of the survival models (models 4 to 6)

	Univariate model 7	Multivariate model 7	Univariate model 8	Multivariate model 8
Model	Cox PH	Frailty (gaussian random effect)	Cox PH	Frailty (gaussian random effect)
Intent to share (yes)	0.275 (0.218) p = 0.207	0.2644 (0.2218) p = 0.23	-0.007 (0.168) p = 0.966	0.005486 0.1962 0.980
Intervention type (device)				
Intervention type (drug)				
Geographical zone (Europe)				
Geographical zone (other)				
Geographical zone (USA)				
Control group type (inactive)				-0.511702 0.2235 0.022
Medical specialty (surgery)				0.771866 0.6077 0.2
Primary outcome (positive)				
Funding source (charity)				
Funding source (industry)				
Funding source (mixed)				
Sample size				
Observations	185	185	185	185
Log likelihood	-435.912	-431.600	-650.813	-619.293
AIC	873.823	867.200	1303.626	1246.586

Appendix Table 6: Details of the survival models (models 7 and 8)

WEB-APPENDIX 3

REFRENCES (PRIMARY RCTs & RE-USES) …		FUNDERS
… WITH A REPRODUCIBLE RESEARCH STATEMENT INDICATING NO INTENTION TO SHARE DATA		
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. (PRIMARY RCT)		AstraZeneca and Bristol-Myers Squibb
	Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.	AstraZeneca
	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.	AstraZeneca
	Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.	Authors are employees of AstraZeneca
	Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C	AstraZeneca
	Cystatin C- and Creatinine-Based Estimates of Glomerular Filtration Rate in Dapagliflozin Phase 3 Clinical Trials.	AstraZeneca
Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. (PRIMARY RCT)		Abbott
	Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.	Abbvie (Due to the split of Abbott, Humira rights are now owned by AbbVie)
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.		Pfizer
	Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.	Pfizer
	Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.	Pfizer
	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.	Pfizer
	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.	Pfizer
	Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.	Pfizer
Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. (PRIMARY RCT)		Pfizer
	Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo-controlled studies of varenicline.	Pfizer
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. (PRIMARY RCT)		Merck & Co
	Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.	In part by National Natural Science Foundation of China (nos. 81473029, 81502853, and 81473028), Natural Science Foundation of Jiangsu Province (BK20151026), Medical Reform Project of Health and Family Planning Commission of Jiangsu Province of China (YG201413), and Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions.

… WITH A REPRODUCIBLE RESEARCH STATEMENT INDICATING AN INTENTION TO SHARE DATA		
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. (PRIMARY RCT)		National Institute of Allergy and Infectious Diseases
	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.	Support and funding for this study come from Grupo de Estudio de SIDA (GESIDA), Sociedad Espanola de Enfermedades Infecciosas y Microbiología Clínica (SEIMC)(AIDS Study Group, Spanish Society for Infectious Diseases and Clinical Microbiology). The study benefited from the scientific sponsorship and support of the Red de Investigación en SIDA (AIDS Research Network) (RIS; RD06/0006 and RD12/0017)
	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.	Supported by Grupo de Estudio del SIDA (AIDS Study Group, GESIDA) of the Sociedad Espanola de Enfermedades Infecciosas y Microbiología Cínica (Spanish Society of Infectious Diseases and Clinical Microbiology, SEIMC), and Red de Investigación en SIDA (AIDS Research Network) (RIS; RD06/0006 and RD12/0017).

Appendix Table 7: Details of funders for primary RCTs and their re-use for the outcome "MIPD/pooled analyses which have no author in common with the primary RCT"

WEB-APPENDIX 4

DETAILS OF THE COUNT OUTCOME MODELS

4.3 **4.4** **4.5** **4.6** **4.7**	**Secondary**	Number and type of secondary use - in which lead authors (first, corresponding and last) of the paper were outside the team authoring the original Annals paper - by a team where 0, <50%, ≥50% or 100% of authors are from the original Annals paper
Dependent variable		2 models will be performed for each author criteria: 1/ Number of reuses in a secondary analysis (team no lead authors: **model 9**; team 0: **model 12**; team <50%: **model 15**; team ≥50%: **model 18**; team 100%: **model 21**). 2/ Number of reuses in a meta-analysis on individual patient data or pooled analysis (team no lead authors: **model 10**; team 0: **model 13**; team <50%: **model 16**; team ≥50%: **model 19**; team 100%: **model 22**). As there was no re-analysis, this outcome won't be explored by modelling. *Supplementary analysis:* Number of reuses in a meta-analysis on aggregate data (team no lead authors: **model 11**; team 0: **model 14**; team <50%: **model 17**; team ≥50%: **model 20**; team 100%: **model 23**).
Explanatory variable of interest		Intent to share (binary variable)
Other explanatory variables		Year of publication (will be taken into account using an offset corresponding to the difference between publication date and date of citation searches), geographical zone, intervention type, control group type, medical specialty, result on the primary outcome, funding source, sample size

4.9	**Secondary**	Number of citations
Dependent variable		Number of citations (**model 24**)
Explanatory variable of interest		Intent to share (binary variable)
Other explanatory variables		Year of publication (will be taken into account using an offset corresponding to the difference between publication date and date of citation searches), geographical zone, intervention type, control group type, medical specialty, result on the primary outcome, funding source, sample size

Appendix Table 8: Reminder of the statistical analysis plan for the models 9 to 24

	Univariate model 9	Multivariate model 9	Univariate model 10	Multivariate model 10	Univariate model 11	Multivariate model 11
Model	Negative binomial	Mixed negative binomial	Negative binomial	Negative binomial	Negative binomial	Mixed negative binomial
intent_to_shareyes	-0.246 (0.655)	-0.206 (0.674)	-1.033 (0.679)	0.186 (0.658)	-0.443 (0.192)	-0.265 (0.194)
	p = 0.707	p = 0.760	p = 0.128	p = 0.778	p = 0.021	p = 0.172
intervention_typedevice		1.200 (1.483)		1.186 (1.676)		
		p = 0.419		p = 0.480		
intervention_typedrug		1.093 (0.741)		1.507 (0.813)		
		p = 0.141		p = 0.064		
geographical_zoneEurope						0.318 (0.394)
						p = 0.420
geographical_zoneother						-0.295 (0.479)
						p = 0.538
geographical_zoneUSA						0.214 (0.387)
						p = 0.581
control_group_typeinactive						-0.446 (0.216)
						p = 0.039
medical_specialtysurgery						0.917 (0.543)
						p = 0.092
primary_outcomepositive				1.588 (0.844)		0.296 (0.203)
				p = 0.060		p = 0.146
funding_sourcecharity		0.896 (1.490)		-31.620 (4,334,661.000)		-0.077 (0.421)
		p = 0.548		p = 1.000		p = 0.855
funding_sourceindustry		-0.063 (1.125)		1.737 (0.872)		0.437 (0.275)
		p = 0.956		p = 0.047		p = 0.113
funding_sourcemixt		1.334 (0.780)		0.443 (0.794)		-0.230 (0.212)
		p = 0.088		p = 0.577		p = 0.280
sample_size						-0.156 (0.127)
						p = 0.219
Constant	-3.636 (0.483)	-6.361 (1.212)	-2.972 (0.475)	-6.656 (1.163)	-0.804 (0.140)	-1.138 (0.450)
	p = 0.000	p = 0.00000	p = 0.000	p = 0.000	p = 0.000	p = 0.012
Observations	185	185	185	185	185	185
Log Likelihood	-66.397	-43.061	-72.291	-64.088	-339.210	-115.388
theta	0.091 (0.044)		0.073 (0.029)	0.161 (0.071)	0.916 (0.156)	
Akaike Inf. Crit.	136.793	104.122	148.583	144.175	682.420	258.776

Appendix Table 9: Details of the count outcome models (models 9 to 11)

	Univariate model 12	Multivariate model 12	Univariate model 13	Multivariate model 13	Univariate model 14	Multivariate model 14
Model	Poisson	Poisson	Negative binomial	Mixed negative binomial	Negative binomial	Mixed negative binomial
intent_to_shareyes	-0.989 (1.225)	-1.121 (1.253)	-2.051 (1.142)	-3.365 (1.481)	-0.450 (0.195)	-0.296 (0.198)
	p = 0.419	p = 0.371	p = 0.073	p = 0.023	p = 0.021	p = 0.134
intervention_typedevice		19.047 (2,442.071)				
		p = 0.994				
intervention_typedrug		17.098 (2,442.071)				
		p = 0.995				
geographical_zoneEurope						0.439 (0.406)
						p = 0.280
geographical_zoneother						-0.171 (0.492)
						p = 0.728
geographical_zoneUSA						0.321 (0.400)
						p = 0.422
control_group_typeinactive						-0.435 (0.220)
						p = 0.048
medical_specialtysurgery						0.935 (0.551)
						p = 0.090
primary_outcomepositive						0.287 (0.206)
						p = 0.164
funding_sourcecharity						-0.041 (0.426)
						p = 0.924
funding_sourceindustry						0.365 (0.282)
						p = 0.196
funding_sourcemixt						-0.265 (0.216)
						p = 0.221
sample_size						-0.147 (0.126)
						p = 0.243
Constant	-5.450 (0.707)	-22.274 (2,442.071)	-3.443 (0.727)	-4.811 (1.543)	-0.829 (0.142)	-1.249 (0.461)
	p = 0.000	p = 0.993	p = 0.00001	p = 0.002	p = 0.000	p = 0.007
Observations	185	185	185	185	185	185
Log Likelihood	-17.261	-14.620	-36.357	-27.144	-334.814	-116.315
theta			0.029 (0.017)		0.885 (0.152)	
Akaike Inf. Crit.	38.522	37.240	76.714	62.287	673.628	260.630

Appendix Table 10: Details of the count outcome models (models 12 to 14)

	Univariate model 15	Multivariate model 15	Univariate model 16	Multivariate model 16	Univariate model 17	Multivariate model 17
Model	Negative binomial	Negative binomial	Negative binomial	Negative binomial	Negative binomial	Mixed negative binomial
intent_to_shareyes	-0.424 (0.443)	-0.294 (0.439)	-0.885 (0.619)	0.408 (0.588)	-0.441 (0.188)	-0.260 (0.190)
	p = 0.338	p = 0.504	p = 0.153	p = 0.488	p = 0.019	p = 0.170
geographical_zoneEurope		-0.284 (0.959)				0.312 (0.384)
		p = 0.767				p = 0.417
geographical_zoneother		-0.290 (1.116)				-0.382 (0.469)
		p = 0.795				p = 0.416
geographical_zoneUSA		0.762 (0.881)				0.147 (0.377)
		p = 0.388				p = 0.697
control_group_typeinactive						-0.478 (0.211)
						p = 0.024
medical_specialtysurgery		-28.707 (1,048,977.000)				0.806 (0.532)
		p = 1.000				p = 0.130
intervention_typedevice				1.057 (1.463)		
				p = 0.471		
intervention_typedrug				1.481 (0.685)		
				p = 0.031		
primary_outcomepositive				1.287 (0.687)		0.245 (0.197)
				p = 0.061		p = 0.215
funding_sourcecharity				-31.359 (2,588,090.000)		-0.130 (0.414)
				p = 1.000		p = 0.755
funding_sourceindustry				1.570 (0.764)		0.447 (0.270)
				p = 0.040		p = 0.099
funding_sourcemixt				-0.041 (0.684)		-0.210 (0.208)
				p = 0.952		p = 0.311
sample_size						-0.163 (0.126)
						p = 0.198
Constant	-2.474 (0.324)	-2.933 (0.844)	-2.516 (0.446)	-5.759 (0.938)	-0.772 (0.137)	-0.993 (0.438)
	p = 0.000	p = 0.001	p = 0.00000	p = 0.000	p = 0.00000	p = 0.024
Observations	185	185	185	185	185	185
Log Likelihood	-131.826	-128.791	-95.934	-85.995	-344.329	-113.628
theta	0.171 (0.051)	0.198 (0.060)	0.077 (0.025)	0.162 (0.058)	0.965 (0.164)	
Akaike Inf. Crit.	267.652	269.583	195.867	187.991	692.657	255.255

Appendix Table 11: Details of the count outcome models (models 15 to 17)

	Univariate model 18	Multivariate model 18	Univariate model 19	Multivariate model 19	Univariate model 20	Multivariate model 20
Model	Negative binomial	Mixed negative binomial	Negative binomial	Mixed negative binomial	Negative binomial	Negative binomial
intent_to_shareyes	0.561 (0.282)	0.520 (0.293)	0.967 (0.914)	0.770 (0.908)	-0.573 (0.786)	-0.858 (0.780)
	p = 0.046	p = 0.076	p = 0.290	p = 0.397	p = 0.466	p = 0.271
geographical_zoneEurope				-1.748 (1.018)		35.268 (18,565,057)
				p = 0.086		p = 1.000
geographical_zoneother				-2.007 (1.442)		34.028 (18,565,057)
				p = 0.164		p = 1.000
geographical_zoneUSA				-2.989 (1.115)		32.523 (18,565,057)
				p = 0.008		p = 1.000
medical_specialtysurgery						0.967 (1.477)
						p = 0.513
Constant	-2.235 (0.221)	-2.703 (0.271)	-5.044 (0.753)	-4.003 (1.057)	-4.340 (0.544)	-38.479 (18,565,057)
	p = 0.000	p = 0.000	p = 0.000	p = 0.0002	p = 0.000	p = 1.000
Observations	185	185	185	185	185	185
Log Likelihood	-227.026	-114.198	-41.334	-26.367	-39.661	-34.120
theta	0.484 (0.114)		0.062 (0.039)		0.110 (0.101)	0.279 (0.286)
Akaike Inf. Crit.	458.051	236.397	86.668	66.734	83.322	80.239

Appendix Table 12: Details of the count outcome models (models 18 to 20)

	Univariate model 21	Multivariate model 21	Univariate model 22	Univariate model 23	Univariate model 24	Multivariate model 24
Model	Negative binomial	Negative binomial	Exact Poisson	Exact Poisson	Negative binomial	Mixed negative binomial
intent_to_shareyes	0.856 (0.551)	0.817 (0.538)	Inf [0.02-Inf]	0 [0.0-29.0]	-0.192 (0.107)	-0.102 (0.115)
	p = 0.121	p = 0.129	p = 1.000	p = 0.426	p = 0.075	p = 0.37
intervention_typedevice						0.018 (0.287)
						p = 0.951
intervention_typedrug						0.121 (0.133)
						p = 0.364
control_group_typeinactive		1.111 (0.763)				0.040 (0.135)
		p = 0.146				p = 0.765
funding_sourcecharity		-31.836 (4,850,389)				-0.168 (0.255)
		p = 1.000				p = 0.510
funding_sourceindustry		-0.153 (0.850)				0.355 (0.194)
		p = 0.857				p = 0.068
funding_sourcemixt		0.819 (0.528)				0.110 (0.138)
		p = 0.121				p = 0.425
sample_size						-0.074 (0.053)
						p = 0.164
Constant	-4.517 (0.471)	-5.750 (0.883)			2.793 (0.081)	2.535 (0.149)
	p = 0.000	p = 0.000			p = 0.000	p = 0.000
Observations	185	185	185	185	185	185
Log Likelihood	-68.816	-64.473			-961.429	-93.102
theta	0.586 (0.659)	1.387 (2.439)			1.976 (0.198)	
Akaike Inf. Crit.	141.632	140.945			1,926.858	208.203

Appendix Table 13: Details of the count outcome models (models 21 to 24)

WEB-APPENDIX 5



Appendix Figure 1: Number of re-uses where the first, last and corresponding authors were not among the authors of the primary article in the Annals